论文部分内容阅读
目的:评价康复新液与利巴韦林气雾剂联用对小儿手足口病患者的临床疗效。方法:选取2009年4月—2011年4月间收治的小儿手足口病患者78例,将其分为观察组和对照组,每组39例;观察组患者给予康复新液与利巴韦林气雾剂联用治疗,对照组患者给予利巴韦林气雾剂治疗,比较两组患者的临床疗效。结果:观察组患者临床治疗的总有效率为84.62%显著高于对照组为64.10%(P<0.05);观察组患者的热退时间、皮疹消失时间及住院时间均显著短于对照组(P<0.05)。结论:康复新液与利巴韦林气雾剂联用治疗小儿手足口病患者的临床疗效优于单用利巴韦林气雾剂,且明显缩短了患者的热退时间、皮疹消失时间和住院时间,减轻了患儿痛苦,加快了患者康复,使用较安全。
Objective: To evaluate the clinical efficacy of Kangfuxin and ribavirin aerosol in children with hand-foot-mouth disease. Methods: From April 2009 to April 2011, 78 children with HFMD were enrolled in this study. They were divided into observation group and control group, 39 cases in each group. The patients in observation group were given Kangfuxin and ribavirin Aerosol combination therapy, the control group of patients given ribavirin aerosol treatment, the clinical efficacy of the two groups were compared. Results: The total effective rate of clinical treatment in observation group was 84.62%, which was significantly higher than that in control group (64.10%, P <0.05). The thermal back-off time, disappearance of rash and hospitalization time in observation group were significantly shorter than those in control group <0.05). Conclusion: The clinical efficacy of Kangfuxin and ribavirin aerosol in treating children with hand-foot-mouth disease is better than that of ribavirin alone aerosol, and significantly shorten the time of patients with fever back, the disappearance of rash and Hospitalization, reduce the suffering of children, speed up the rehabilitation of patients, the use of safer.